Clinical Trial Update: Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This Phase 2 neoadjuvant study of anti-PD-1 immunotherapy in resectable non-small cell lung cancer has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-1 inhibitor (anti-PD-1 immunotherapy)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2025-04-04